Seroprevalence Investigation of Hepatitis B and Hepatitis B Core Antigen in Oncology Patients
VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, cilt.26, sa.3, ss.110-113, 2020 (ESCI, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 26 Sayı: 3
- Basım Tarihi: 2020
- Doi Numarası: 10.4274/vhd.galenos.2020.2019.0036
- Dergi Adı: VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.110-113
- Anahtar Kelimeler: Hepatitis B reactivation, oncology, immunosuppressive treatments, prophylactic antiviral treatments, REACTIVATION
- Ankara Üniversitesi Adresli: Evet
Özet
Objectives: Hepatitis B virus (HBV) affects a significant part of society and is characterized by high mortality and morbidity. Hepatitis B affects approximately 350 million people worldwide, many of whom are chronic patients. Especially being under immunosuppressive therapy is a risk factor for the reactivation of the disease. The aim of this study was to investigate the seroprevalence of HB in oncology patients.